Reporting Period: June 22 – June 28, 2026
In the 4th week of June 2026, global medical device and MedTech news highlighted significant developments in surgical robots, structural heart disease, wearable regulations, neurotech, and recall/safety information.
Notably, this week's key news included LEM Surgical's FDA 510(k) clearance for its spine surgery robot, Johnson & Johnson's initiation of a carotid IVL clinical trial, Valgen Medtech's CE Mark approval for its mitral valve repair device, and the termination of Whoop's FDA warning letter regarding its blood pressure estimation feature.
1. LEM Surgical Obtains New FDA 510(k) Clearance for Dynamis Spinal Surgery Robot
LEM Surgical has obtained a new FDA 510(k) clearance for its Dynamis robotic surgical system.
This latest clearance adds individual vertebral body tracking, a stabilized workflow with dual arms, and cervical spine indications in the field of spinal surgery. Dynamis is a navigation-based robotic platform characterized by a configuration featuring three robotic arms.
For surgical assistance robots, competitiveness isn't just about introducing robotic arms; it also relies on intraoperative navigation, real-time tracking, and integration with the surgical workflow. In the spinal and orthopedic fields, robotic-assisted surgery is expected to continue advancing in sophistication.
Source: MassDevice - LEM Surgical wins new FDA clearance for humanoid surgical robot
2. Johnson & Johnson Initiates Clinical Trial Enrollment for Carotid IVL System
Johnson & Johnson has begun enrollment for the SKYWARD clinical program, evaluating the SkyRunner carotid IVL system, which utilizes Shockwave IVL technology.
This FDA IDE study will assess a carotid-specific IVL system for calcified carotid lesions prior to stent placement. While IVL is a calcified lesion treatment technology that has expanded in the coronary and peripheral vascular fields, its application to the carotid artery represents a new development.
In the carotid region, device selection for calcified lesions, embolic risk, and the safety of pre-stent placement procedures are crucial. This move indicates that the expansion of IVL technology's indications is gaining momentum following J&J's acquisition of Shockwave.
Source: MassDevice - Johnson & Johnson begins carotid IVL study enrollment
3. Valgen Medtech Secures European CE Mark for DragonFly Mitral Valve Repair System
China's Valgen Medtech has obtained the European CE Mark for its DragonFly transcatheter mitral valve repair system, indicated for functional mitral regurgitation (FMR).
The company had previously received a CE Mark in 2025 for degenerative mitral regurgitation (DMR). With this latest approval, DragonFly now holds European approval for both DMR and FMR.
In the structural heart disease field, transcatheter treatments for the mitral and tricuspid valve areas are expanding, following the trend set by TAVR. The fact that a structural heart device originating from China has obtained European approval indicates a shift in global competition.
Source: MassDevice - Valgen earns CE mark for mitral valve repair system
4. Johnson & Johnson Launches ThermoCool SmartTouch Dual-Energy Ablation Catheter in Europe
Johnson & Johnson has launched its ThermoCool SmartTouch dual-energy ablation catheter platform in Europe.
This platform is one of the ablation technologies used in atrial fibrillation treatment and is a product related to J&J's Biosense Webster division. In the cardiac electrophysiology field, multiple technologies are competing, including radiofrequency, pulsed-field ablation, and dual-energy types.
The European launch indicates J&J's move to strengthen its product portfolio in the EP (electrophysiology) sector.
Source: MassDevice - Johnson & Johnson launches ThermoCool SmartTouch ablation tech in Europe
5. FDA Lifts Warning Letter Against Whoop Over Blood Pressure Estimation Feature
Wearable company Whoop has revealed that the FDA has officially closed the warning letter it issued regarding Whoop's Blood Pressure Insights feature.
In 2025, the FDA had issued a warning letter, stating that Whoop's blood pressure estimation feature might qualify as an unapproved medical device function. Subsequently, Whoop reportedly revised its displays and functions, modifying them to meet the FDA's requirements for general wellness products.
This case highlights the critical distinction between general health management functions and medical device functions in wearables and healthcare apps. Particular caution is necessary regarding expressions related to the diagnosis and management of diseases, such as blood pressure, blood sugar, ECG, and sleep apnea.
Source: MedTech Dive - FDA drops Whoop warning letter over blood pressure feature
6. Modular Medical Launches Pivot Tubeless Insulin Patch Pump in the U.S.
Modular Medical has launched its Pivot tubeless insulin patch pump in the United States. Pivot received FDA 510(k) clearance in April 2026, and the company positions it as the only fully electronic tubeless insulin pump available in the U.S.
In the diabetes field, treatment management is advancing through the combination of CGMs, insulin pumps, smartphone apps, and algorithms. Tubeless pumps offer high patient value in terms of wearability and ease of use in daily life.
Source: MassDevice - Modular Medical launches Pivot tubeless pump
7. Tissium Raises Approximately $68 Million for Tissue Reconstruction Polymer Technology
Tissium has raised approximately $68 million in funding for the development and commercialization of its polymer technology for tissue reconstruction.
The company develops polymer technologies that support tissue adhesion and reconstruction, including sutureless nerve repair. In the surgical field, advancements in sutures, staples, adhesives, sealants, and reconstructive materials directly lead to reduced operating times and less invasive procedures.
Even in a selective funding environment, it is clear that medical device and biomaterial companies with clear clinical needs and platform potential are attracting investment.
Source: MassDevice - Tissium closes $68M financing for tissue reconstruction polymers
8. NeuroLife Launches as a Wearable Neurotech Company for Stroke and Spinal Cord Injury Rehabilitation
NeuroLife, a company born from a partnership between Battelle and The NeuroTech Institute, is developing non-invasive neurotechnology to assist in the recovery of motor function after stroke and spinal cord injury. The company reportedly secured approximately $2.9 million in funding for its launch.
In the field of rehabilitation, combining wearable devices, electrical stimulation, AI analysis, and home monitoring has the potential to shift from traditional facility-based rehabilitation to continuous, personalized recovery support.
Source: MassDevice - Wearable neurotech company NeuroLife launches with $2.9M
9. Coherence Neuro Initiates First Clinical Trial for Brain-Computer Interface
Coherence Neuro has initiated its first-in-human clinical trial for the Cipher brain-computer interface (BCI).
Cipher is a bidirectional BCI that records brain activity and delivers electrical stimulation using a flexible, high-density, thin-film cortical probe. In the BCI field, an increasing number of companies are aiming for clinical applications targeting neurological disorders, motor function impairments, and communication assistance.
While BCIs hold great promise, they also present complex challenges regarding invasiveness, long-term safety, signal stability, data processing, ethical considerations, and regulatory evaluation criteria. The design of early clinical trials significantly impacts future commercialization.
Source: MassDevice - Coherence Neuro begins first clinical study for BCI
10. FDA Updates Information on Impella-Related Device Modifications and Medical Device Recalls/Early Alerts
The FDA has updated its Medical Device Recalls and Early Alerts information, including updates to the instructions for use for Abiomed's Automated Impella Controllers. Safety measures concerning Impella controllers and peripheral devices are ongoing.
For high-risk medical devices like cardiac assist devices, which are critical for life support, risk management is required to encompass usage instructions, alarms, accessories, training, and on-site response procedures.
For manufacturers, a robust system for post-market safety information surveillance, complaint handling, field actions, user notifications, and package insert/IFU revisions is crucial.
Source: FDA - Medical Device Recalls and Early Alerts
Practical Implications
From this week's news, there are four major important implications for medical device companies.
1. Surgical Robots: From "Standalone Robot" to "Workflow Integration"
As seen with LEM Surgical's Dynamis, surgical robots are moving beyond mere arm control. Navigation, intraoperative tracking, compatibility with surgical instruments and implants, and ease of setup within the operating room are becoming crucial.
When introducing such devices to the Japanese market, it's essential to consider not only regulatory classification and clinical evaluation but also existing operating room workflows, facility implementation costs, training systems, and maintenance structures.
2. Continued Expansion of Indications in Structural Heart Disease and Endovascular Therapy
In the cardiovascular field, we continue to see the expansion of indications for existing technologies and the launch of new platforms, such as J&J's carotid IVL, Valgen's mitral valve repair device, and J&J's ablation catheters.
In this area, not only regulatory approval but also clinical evidence, operator training, reimbursement, and facility standards significantly influence market adoption.
3. Wearables: Display and Advertising Expressions Pose Regulatory Risks
The case of Whoop illustrates that, for wearables and digital health products, not only the product itself but also its advertising expressions and user-facing explanations can become regulatory issues.
It is crucial to clearly define from the early stages of development whether the product will be launched as a general wellness product or whether it will seek approval/certification as a medical device.
4. Neurotech/BCI: Funding and Clinical Development Advance, but Evaluation Design Remains a Challenge
The activities of NeuroLife and Coherence Neuro indicate that investment and clinical development in the neurotech sector are progressing.
However, for BCI and neurostimulation devices, it is crucial to establish clear frameworks for evaluating effectiveness, long-term safety, usability, data management, and ethical considerations. When considering introduction into Japan, a strategic design is necessary that takes into account not only simple medical device classification but also clinical significance and the intended use environment.
Summary
In the medical device news for the fourth week of June 2026, significant developments were observed concerning surgical robots, cardiovascular devices, wearables, neurotech, and recall/safety information.
Notably, LEM Surgical's FDA clearance, J&J's initiation of a carotid IVL trial, Valgen's CE mark acquisition, the termination of Whoop's FDA warning letter, and neurotech-related news from NeuroLife and Coherence Neuro all indicate the future direction of the MedTech market.
For medical device companies, designing not only regulatory approval but also clinical evidence, labeling and advertising claims, insurance reimbursement, post-market safety, and workflow integration at the point of care, all as an integrated process, will lead to competitiveness in the global market.
MK Consulting provides practical support for market entry into Japan, medical device regulatory applications, clinical evaluation, correspondence with PMDA and registered certification bodies, and clarification of insurance reimbursement issues. We also offer initial consultations for overseas medical device manufacturers expanding into Japan and Japanese companies expanding overseas.